<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331263</url>
  </required_header>
  <id_info>
    <org_study_id>R17-023</org_study_id>
    <nct_id>NCT03331263</nct_id>
  </id_info>
  <brief_title>Single Dose CHG Pharmacokinetic Study</brief_title>
  <official_title>Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medline Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medline Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single 2% topical application of ReadyPrep® CHG was applied on either the abdomen
      (Treatment-1) or the groin (Treatment-2) whereas Treatment-3 consisted of a control treatment
      where the same procedure as Treatment-1 and -2 was performed, but without the topical
      application of ReadyPrep® CHG. The treatments were separated by a wash-out of 7 calendar
      days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Actual">August 6, 2017</completion_date>
  <primary_completion_date type="Actual">August 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>laboratory-blinded, 3-period, 3-sequence, crossover study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with plasma levels of chlorexidine following systemic exposure after a single topical application of CHG.</measure>
    <time_frame>Up to 24 hours after application</time_frame>
    <description>A total of 12 blood samples will be collected (one tube of 6 mL each) in each study period and analyzed for plasma levels of chlorhexidine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with of treatment emergent adverse events.</measure>
    <time_frame>Up to 24 hours after application</time_frame>
    <description>Number of subjects with treatment related adverse events as assessed by System Organ Class (SOC) and Preferred Term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Surgical Skin Preparation</condition>
  <arm_group>
    <arm_group_label>Abdominal application of 2% CHG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Groin application of 2% CHG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control treatment with no application</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>2% CHG</description>
    <arm_group_label>Abdominal application of 2% CHG</arm_group_label>
    <arm_group_label>Groin application of 2% CHG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects were male or female, aged ≥ 18 and ≤ 60 years (inclusive). The main inclusion
             criteria were:

               -  non- or ex-smokers

               -  body mass index (BMI) ≥19.00 kg/m2 and ≤32.00 kg/m2 and a body weight ≥ 55 kg

               -  negative pregnancy test for female subjects

               -  healthy according to medical history, complete physical examination (including
                  vital signs and skin examination) and laboratory tests (general biochemistry,
                  hematology and urinalysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Carlson, Pharm D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma USA LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma USA LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

